SequelSEC

Immunocore Holdings plc IMCR

Biological Products, (No Diagnostic Substances) · CIK 0001671927 · Fiscal year ends 1231

Revenue
$430.78M
Fiscal year ended 2026-06-30
Operating income
-$22.58M
Fiscal year ended 2026-06-30
Free cash flow
-$41.15M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.50BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$29.59Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin98.7%85th
FCF margin-3.8%81th
Operating margin-11.3%81th
SBC / revenue9.4%20th
Net margin-8.9%77th
CapEx / revenue1.1%24th
R&D / revenue68.7%26th
Revenue YoY growth29.0%65th
Current ratio4.04x48th

Immunocore Holdings plc (IMCR) reported revenue of $430.78M and net income of -$18.07M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Immunocore Holdings plc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Immunocore Holdings plc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$430.78M
Cost of revenue$4.74M
Gross profit$426.04M
Operating income-$22.58M
Net income-$18.07M
Research & development$284.45M
Weighted-average diluted sharesUnavailable
Pretax income-$2.73M
Income tax expense$15.34M
Diluted EPSUnavailable
Selling, general & administrative$164.16M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Immunocore Holdings plc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$484.92M
Total assets$1.12B
Current assets$1.05B
Total liabilities$699.62M
Current liabilities$235.20M
Total equity incl. NCI$419.80M
Temporary (mezzanine) equityUnavailable
Inventory$7.79M
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$26.32M

Cash flow

Immunocore Holdings plc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$34.96M
Capital expenditures$6.20M
Investing cash flow$7.80M
Financing cash flow$23.29M
Net change in cashUnavailable
Stock-based compensation$33.88M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Immunocore Holdings plc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$41.15M
Gross margin98.9%
Operating margin-5.2%
FCF margin-9.6%
SBC / revenue7.9%
Current ratio4.47x
Revenue YoY growth21.0%
Net margin-4.2%
R&D / revenue66.0%
CapEx / revenue1.4%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMCR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.